Evaluation of Safe and Immunogenic Dose of AD Vaccine in aged non-human primates: Prelude to Phase 1 Preventive Vaccinations

AD 疫苗在老年非人灵长类动物中的安全和免疫原性剂量评估:第一阶段预防性疫苗接种的前奏

基本信息

  • 批准号:
    10433497
  • 负责人:
  • 金额:
    $ 41.95万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-02-01 至 2023-01-31
  • 项目状态:
    已结题

项目摘要

Project Summary Immunotherapy is still considered a very promising therapeutic strategy for AD prevention when certain conditions are met. Data from various immunotherapeutic studies support our long- standing tenet that immunogenic AD vaccines could at least delay disease progression when they target both Aβ and Tau pathological molecules at an early stage of the disease before AD manifestation or even in asymptomatic healthy people at risk of AD. Recently FDA announced emergency accelerated approval of mAb Aducanumab for treatment of early AD. However, it is impractical to use very expensive mAbs as a preventive treatment of healthy subjects due to the need for frequent (monthly) administration of high concentrations (700-800mg per IV injection) of this immunotherapeutic. In contrast, almost all effective vaccines are effective when they are used as a preventive treatment. Accordingly, in this administrative supplement to U01 AG060965, we propose to test the overall safety and immunogenicity of a dual vaccine (DUVAC) targeting Aβ and Tau in non-human primates that more closely resemble the human immune system. These data will support the submission of INDs to the FDA for future clinical trials that will allow us to treat asymptomatic healthy subjects at risk to MCI with extremely immunogenic Aβ and tau vaccines based on the same and very immunogenic MultiTEP platform and novel adjuvant AdvaxCpG. Our proprietary vaccine platform can stimulate adaptive immunity, providing broad coverage of human MHC polymorphisms and activating both naive Th cells and pre-existing memory Th cells generated in response to conventional vaccines and/or infections with various pathogens during one's lifespan without the activation of harmful autoreactive T cells. These "non-self" Th cells should activate B cells and induce the production of therapeutically potent antibodies specific to pathological Aβ and Tau in humans, similar to that in non-human primates. Completing studies in aged monkeys along with data from AG060965 safety/toxicology studies in diseased mice should strongly support our IND submission for the first-in-human preventive dual Aβ/tau vaccine with healthy people at risk of MCI or earlier based on research blood, CSF, brain biomarkers.
项目摘要 免疫疗法仍然被认为是预防AD的非常有前途的治疗策略, 满足某些条件。来自各种免疫学研究的数据支持我们的长期- 免疫原性AD疫苗至少可以延缓疾病进展, 在AD之前的疾病早期阶段靶向Aβ和Tau病理分子 表现,甚至在无症状的健康人在AD的风险。FDA最近宣布, 紧急加速批准mAb Aducanumab用于治疗早期AD。但据 使用非常昂贵的mAb作为健康受试者的预防性治疗是不切实际的, 需要频繁(每月)给予高浓度(700- 800 mg/IV注射)的 这种免疫力。相比之下,几乎所有有效的疫苗在使用时都是有效的 作为预防性治疗。因此,在U 01 AG 060965的行政补充中,我们 拟检测靶向Aβ的双联疫苗(DUVAC)的总体安全性和免疫原性 和Tau在非人类灵长类动物中更接近于人类免疫系统。这些 数据将支持向FDA提交IND,用于未来的临床试验, 用极免疫原性Aβ和tau治疗有MCI风险的无症状健康受试者 基于相同和非常免疫原性的MultiTEP平台和新型佐剂的疫苗 AdvaxCpG。我们专有的疫苗平台可以刺激适应性免疫,提供广泛的 覆盖人类MHC多态性并激活幼稚Th细胞和预先存在的Th细胞, 响应于常规疫苗和/或各种感染而产生的记忆Th细胞 病原体在一个人的寿命没有激活有害的自身反应性T细胞。这些 “非自身”Th细胞应激活B细胞并诱导产生治疗上有效的 人类中对病理性Aβ和Tau具有特异性的抗体,类似于非人灵长类动物中的抗体。 沿着在老年猴中完成研究,并获得AG 060965安全性/毒理学研究的数据, 患病小鼠应该强烈支持我们的IND提交的第一个在人类预防双重 Aβ/tau疫苗用于有MCI或更早风险的健康人群,基于研究血液、CSF、脑 生物标志物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael G Agadjanyan其他文献

Expression of the Epigenetic factor BORIS (CTCFL) in the Human Genome
  • DOI:
    10.1186/1479-5876-9-213
  • 发表时间:
    2011-12-01
  • 期刊:
  • 影响因子:
    7.500
  • 作者:
    Rosalia de Necochea-Campion;Anahit Ghochikyan;Steven F Josephs;Shelly Zacharias;Erik Woods;Feridoun Karimi-Busheri;Doru T Alexandrescu;Chien-Shing Chen;Michael G Agadjanyan;Ewa Carrier
  • 通讯作者:
    Ewa Carrier

Michael G Agadjanyan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael G Agadjanyan', 18)}}的其他基金

Manufacturing of New Batch AV-1959D Drug Product and Placebo for Phase 1 Trial
为 1 期试验生产新批次 AV-1959D 药品和安慰剂
  • 批准号:
    10732215
  • 财政年份:
    2022
  • 资助金额:
    $ 41.95万
  • 项目类别:
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
首个人类 Aβ DNA 疫苗的安全性/耐受性/免疫原性,AV-1959D 在早期 AD 受试者中的 1 期试验:基于 FDA 批准的 IND18953。
  • 批准号:
    10340654
  • 财政年份:
    2022
  • 资助金额:
    $ 41.95万
  • 项目类别:
Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.
首个人类 Aβ DNA 疫苗的安全性/耐受性/免疫原性,AV-1959D 在早期 AD 受试者中的 1 期试验:基于 FDA 批准的 IND18953。
  • 批准号:
    10571883
  • 财政年份:
    2022
  • 资助金额:
    $ 41.95万
  • 项目类别:
Manufacturing of Drug Product, Dual Aβ/tau Vaccine for Clinical Trials
药品生产,用于临床试验的双重 Aβ/tau 疫苗
  • 批准号:
    10667237
  • 财政年份:
    2019
  • 资助金额:
    $ 41.95万
  • 项目类别:
Cooperative program U01 AG060965 Supplement: "Preparation of IND for Dual Aβ/Tau AD Vaccine for submission to FDA"
合作计划 U01 AG060965 补充:“双 Aβ/Tau AD 疫苗 IND 的准备以提交给 FDA”
  • 批准号:
    10505652
  • 财政年份:
    2019
  • 资助金额:
    $ 41.95万
  • 项目类别:
IND-enabling Preclinical Studies on Anti-Tau AD Vaccine for Phase 1 Trial
抗 Tau AD 疫苗 1 期试验的 IND 临床前研究
  • 批准号:
    10364623
  • 财政年份:
    2019
  • 资助金额:
    $ 41.95万
  • 项目类别:
Repurposing of Universal and Immunogenic MultiTEP Platform Designed for AD to Develop SARS-CoV-2 Multiepitope Vaccine
重新利用专为 AD 设计的通用和免疫原性 MultiTEP 平台来开发 SARS-CoV-2 多表位疫苗
  • 批准号:
    10162389
  • 财政年份:
    2019
  • 资助金额:
    $ 41.95万
  • 项目类别:
Combining AD Epitope Vaccine with Innate Immunity
AD表位疫苗与先天免疫相结合
  • 批准号:
    9439835
  • 财政年份:
    2017
  • 资助金额:
    $ 41.95万
  • 项目类别:
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND
临床前研究以满足 FDA 完成 AV-1959 IND 的要求
  • 批准号:
    8887223
  • 财政年份:
    2015
  • 资助金额:
    $ 41.95万
  • 项目类别:
Pre-clinical study to fulfill FDA requirements for the completion of AV-1959 IND
临床前研究以满足 FDA 完成 AV-1959 IND 的要求
  • 批准号:
    9264954
  • 财政年份:
    2015
  • 资助金额:
    $ 41.95万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 41.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了